Cart is empty New research delves into a traditionally overlooked category of chronic hepatitis B (CHB) patients. While those who are HBeAg-negative with normal ALT levels have been considered low-risk and often excluded from immediate treatment, this study challenges that notion by demonstrating the considerable benefits of ongoing antiviral therapy.
Leave A Comment